Mannkind reported $42.43M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Adma Biologics ADMA:US USD 18.97M 24.11M
Biocryst Pharmaceuticals BCRX:US USD 93.27M 6.98M
Dynavax Technologies DVAX:US USD 106.34M 21.9M
Eli Lilly And LLY:US USD 5.27B 12.8M
Halozyme Therapeutics HALO:US USD 128.4M 10.09M
Immunogen IMGN:US USD 92.8M 17.59M
Insmed INSM:US USD 195.43M 41.89M
Karyopharm Therapeutics KPTI:US USD 66.98M 15.6M
Macrogenics MGNX:US USD 66.69M 1.13M
Mannkind MNKD:US USD 42.43M 3.09M
Merk MRK:US USD 10.97B 1.31B
Minerva Neurosciences NERV:US USD 5.21M 1.76M
Novavax NVAX:US USD 861.77M 192.88M
Novo Nordisk A Fs NVO:US DKK 25.38B 2.51B
Peregrine Pharmaceuticals PPHM:US USD 37.44M 3.48M
Pfizer PFE:US USD 13.23B 2.41B
Xencor XNCR:US USD 65.65M 7.47M